

...TIVE\_VS\_CD8\_SINGLE\_POSITIVE\_THYMOCYTE\_UP, GSE22601\_CD4\_SINGLE\_POSITIVE\_VS\_CD8\_SINGLE\_POSITIVE\_THYMOCYTE\_UP

- HOXA9\_DN.V1\_DN, HOXA9\_DN.V1\_DN
- GSE17186\_MEMORY\_VS\_CD21LOW\_TRANSITIONAL\_BCELL\_UP, GSE17186\_MEMORY\_VS\_CD21LOW\_TRANSITIONAL\_BCELL\_UP
- GSE2770\_IL12\_ACT\_VS\_ACT\_CD4\_TCELL\_48H\_DN, GSE2770\_IL12\_ACT\_VS\_ACT\_CD4\_TCELL\_48H\_DN
- GSE7852\_LN\_VS\_THYMUS\_TREG\_DN, GSE7852\_LN\_VS\_THYMUS\_TREG\_DN
- GOMF\_SINGLE\_STRANDED\_DNA\_BINDING, GOMF\_SINGLE\_STRANDED\_DNA\_BINDING
- GSE31082\_CD4\_VS\_CD8\_SP\_THYMOCYTE\_DN, GSE31082\_CD4\_VS\_CD8\_SP\_THYMOCYTE\_DN
- GOBP\_POSITIVE\_REGULATION\_OF\_DNA\_METABOLIC\_PROCESS, GOBP\_POSITIVE\_REGULATION\_OF\_DNA\_METABOLIC\_PROCESS
- GSE37301\_PRO\_BCELL\_VS GRANULOCYTE MONOCYTE PROGENITOR\_DN, GSE37301\_PRO\_BCELL\_VS GRANULOCYTE MONOCYTE PROGENITOR\_DN
- GSE20366\_TREG\_VS\_NAIVE\_CD4\_TCELL\_HOMEOSTATIC\_CONVERSION\_UP, GSE20366\_TREG\_VS\_NAIVE\_CD4\_TCELL\_HOMEOSTATIC\_CONVERSION\_UP
- GSE2770\_UNTREATED\_VS\_IL12\_TREATED\_ACT\_CD4\_TCELL\_6H\_DN, GSE2770\_UNTREATED\_VS\_IL12\_TREATED\_ACT\_CD4\_TCELL\_6H\_DN
- HP\_IRREGULAR\_HYPERPIGMENTATION, HP\_IRREGULAR\_HYPERPIGMENTATION
- GOBP\_CELLULAR\_RESPONSE\_TO\_LIGHT\_STIMULUS, GOBP\_CELLULAR\_RESPONSE\_TO\_LIGHT\_STIMULUS
- MIR4273, MIR4273
- GOBP\_REGULATION\_OF\_DNA\_RECOMBINATION, GOBP\_REGULATION\_OF\_DNA\_RECOMBINATION
- GOBP\_CELLULAR\_RESPONSE\_TO\_UV, GOBP\_CELLULAR\_RESPONSE\_TO\_UV
- GSE27786\_CD4\_TCELL\_VS\_ERYTHTROBLAST\_DN, GSE27786\_CD4\_TCELL\_VS\_ERYTHTROBLAST\_DN
- MIR4722\_5P, MIR4722\_5P
- GOCC\_CLATHRIN\_COATED\_PIT, GOCC\_CLATHRIN\_COATED\_PIT
- CHANDRAN\_METASTASIS\_TOP50\_UP, CHANDRAN\_METASTASIS\_TOP50\_UP
- LAU\_APOPTOSIS\_CDKN2A\_UP, LAU\_APOPTOSIS\_CDKN2A\_UP
- GOBP\_MIRNA\_METABOLIC\_PROCESS, GOBP\_MIRNA\_METABOLIC\_PROCESS
- MIR8069, MIR8069
- MIR655\_5P, MIR655\_5P
- GOMF\_DNA\_DIRECTED\_DNA\_POLYMERASE\_ACTIVITY, GOMF\_DNA\_DIRECTED\_DNA\_POLYMERASE\_ACTIVITY
- HP\_IMPAIRED\_PROPRIOCEPTION, HP\_IMPAIRED\_PROPRIOCEPTION
- HP\_ABNORMAL\_PROSTATE\_MORPHOLOGY, HP\_ABNORMAL\_PROSTATE\_MORPHOLOGY
- HP\_ABNORMALITY\_OF\_LIPOPROTEIN\_CHOLESTEROL\_CONCENTRATION, HP\_ABNORMALITY\_OF\_LIPOPROTEIN\_CHOLESTEROL\_CONCENTRATION
- HP\_RENAL\_CORTICAL\_CYSTS, HP\_RENAL\_CORTICAL\_CYSTS
- MIR6812\_5P, MIR6812\_5P
- HALMOS\_CEBPA\_TARGETS\_DN, HALMOS\_CEBPA\_TARGETS\_DN
- GOBP\_FUCOSYLATION, GOBP\_FUCOSYLATION
- GAVIN\_PDE3B\_TARGETS, GAVIN\_PDE3B\_TARGETS
- HP\_MUSCLE\_HYPERTROPHY\_OF\_THE\_LOWER\_EXTREMITIES, HP\_MUSCLE\_HYPERTROPHY\_OF\_THE\_LOWER\_EXTREMITIES
- PARK\_OSTEOBLAST\_DIFFERENTIATION\_BY\_PHENYLAMIL\_UP, PARK\_OSTEOBLAST\_DIFFERENTIATION\_BY\_PHENYLAMIL\_UP
- HP\_ABNORMALITY\_OF\_THE\_MUSCULATURE\_OF\_THE\_UPPER\_ARM, HP\_ABNORMALITY\_OF\_THE\_MUSCULATURE\_OF\_THE\_UPPER\_ARM
- HP\_ACQUIRED\_ABNORMAL\_HAIR\_PATTERN, HP\_ACQUIRED\_ABNORMAL\_HAIR\_PATTERN
- HP\_OSTEOLYSIS\_INVOLVING\_BONES\_OF\_THE\_FEET, HP\_OSTEOLYSIS\_INVOLVING\_BONES\_OF\_THE\_FEET
- FULLER\_PBMF\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_18HR\_TO\_48HR\_EARLY\_UP, FULLER\_PBMF\_F\_TULARENSIS\_VACCINE\_LVS\_AGE\_22\_54YO\_18HR\_TO\_48HR\_EARLY\_UP
- HP\_TYPE\_1\_MUSCLE\_FIBER\_ATROPHY, HP\_TYPE\_1\_MUSCLE\_FIBER\_ATROPHY
- WATANABE\_COLON\_CANCER\_MSI\_VS\_MSS\_UP, WATANABE\_COLON\_CANCER\_MSI\_VS\_MSS\_UP
- BLANCO\_MELO\_SARS\_COV\_1\_INFECTION\_MCR5\_CELLS\_DN, BLANCO\_MELO\_SARS\_COV\_1\_INFECTION\_MCR5\_CELLS\_DN
- SCHAVOLT\_TARGETS\_OF\_TP53\_AND\_TP63, SCHAVOLT\_TARGETS\_OF\_TP53\_AND\_TP63